Common bowel cancer test needs age adjustments for younger people

A new study, led by experts at the University of Nottingham, has provided a novel insight into how a commonly used test for bowel cancer performs in people under 50 years of age.

Bowel cancer is the fourth most common cancer and second highest cause of cancer death in the UK (according to Cancer Research UK). Globally, there has been a concerning increase in 'early-onset' bowel cancer (i.e. a diagnosis before age 50), which highlights the importance of improving diagnosis in younger people. This new study, published in the journal Gut, looked at whether FITs (faecal immunochemical tests) are an effective test for bowel cancer (colorectal cancer) in people under 50.

The study was led by Professor David Humes in the School of Medicine and NIHR Nottingham Biomedical Research Centre and supported by international collaborators including COLOREACH-UK and the US based charity Fight Colorectal Cancer.

The results indicate that further work is needed to understand how a person's age should be considered alongside their FIT results to better determine bowel cancer risk and prioritize investigation of those most at risk.

FITs are used by GPs to detect microscopic traces of blood in people's poo who have symptoms of bowel cancer. If the test is 'negative', then the risk of bowel cancer is very low, and no further tests are needed.

If the FIT result is ten or above and patients are referred to the hospital for urgent further tests, such as a camera test (colonoscopy) which is invasive and can be uncomfortable.

Bowel cancer risk varies greatly by age group, yet most research has focused on patients over 50 years. In this new study, experts looked at how well FIT works in patients under 50 years at the current cut-off of ten.

The research team reviewed all available research on FIT in people under 50 who had symptoms that could be caused by bowel cancer and compared the findings with patients over 50 years.

They found twelve studies inclusive of more than 69,000 people under 50 tested with FIT with symptoms. In those under 50 years who had a FIT, only about one in 300 (0.35%) were diagnosed with bowel cancer. In people over 50, the risk was three to seven times higher.

The findings show that FIT is a good test for diagnosing bowel cancer however using the same FIT threshold of ten may not work equally well for all age groups. Many more people under 50 years would need to undergo further invasive tests to find one case of bowel cancer compared with older adults and therefore further research is required to tailor these cut offs so the right patients can be prioritized to accelerate diagnosis.

For the first time, our international research brings together the current evidence base for using stool tests in the diagnosis of patients with symptoms of suspected colorectal cancer with a particular focus on how the test performs by age. Further work is now needed to assess the optimum FIT cut-off or integration of FIT into individualized CRC risk prediction models in patients under 50 years and to examine alternative causes of a raised FIT in younger age groups."

Professor David Humes, senior author of the research

Anjee Davis, MPPA, Chief Executive Officer of Fight Colorectal Cancer, said: "Early-onset colorectal cancer is rising worldwide, and this is exactly the kind of question our Global Research Collaborative was built to answer. By pooling evidence across countries, this team has shown that one FIT threshold may not work equally well for every age group. Fight CRC is proud to have brought this group together, and we look forward to the next steps toward better, more tailored diagnosis for people under 50." 

Source:
Journal reference:

Sharma, M., et al. (2026). Diagnostic performance of faecal immunochemical testing (FIT) for colorectal cancer in symptomatic patients under 50 years tested in primary care: A systematic review. Gut. DOI: 10.1136/gutjnl-2026-339890. https://gut.bmj.com/content/early/2026/11/15/gutjnl-2026-339890

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
American Cancer Society updates prostate cancer screening guidelines